CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy
Descripción del Articulo
Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prom...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2016 |
| Institución: | Consejo Nacional de Ciencia Tecnología e Innovación |
| Repositorio: | CONCYTEC-Institucional |
| Lenguaje: | inglés |
| OAI Identifier: | oai:repositorio.concytec.gob.pe:20.500.12390/959 |
| Enlace del recurso: | https://hdl.handle.net/20.500.12390/959 https://doi.org/10.1016/j.gamo.2016.01.003 |
| Nivel de acceso: | acceso abierto |
| Materia: | Breast cancer CD133 Immunotherapy |
| id |
CONC_c0b41359ea312bfe8d2166015025462c |
|---|---|
| oai_identifier_str |
oai:repositorio.concytec.gob.pe:20.500.12390/959 |
| network_acronym_str |
CONC |
| network_name_str |
CONCYTEC-Institucional |
| repository_id_str |
4689 |
| dc.title.none.fl_str_mv |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| title |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| spellingShingle |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy Tume, L Breast cancer CD133 Immunotherapy |
| title_short |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| title_full |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| title_fullStr |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| title_full_unstemmed |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| title_sort |
CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy |
| author |
Tume, L |
| author_facet |
Tume, L Paco, K Ubidia-Incio, R Moya, J |
| author_role |
author |
| author2 |
Paco, K Ubidia-Incio, R Moya, J |
| author2_role |
author author author |
| dc.contributor.author.fl_str_mv |
Tume, L Paco, K Ubidia-Incio, R Moya, J |
| dc.subject.en.fl_str_mv |
Breast cancer CD133 Immunotherapy |
| topic |
Breast cancer CD133 Immunotherapy |
| description |
Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome. © 2016 Sociedad Mexicana de Oncología. |
| publishDate |
2016 |
| dc.date.accessioned.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.available.none.fl_str_mv |
2024-05-30T23:13:38Z |
| dc.date.issued.fl_str_mv |
2016 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12390/959 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.gamo.2016.01.003 |
| dc.identifier.isi.none.fl_str_mv |
457388700019 |
| url |
https://hdl.handle.net/20.500.12390/959 https://doi.org/10.1016/j.gamo.2016.01.003 |
| identifier_str_mv |
457388700019 |
| dc.language.iso.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.none.fl_str_mv |
Gaceta Mexicana de Oncología |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.none.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.publisher.en.fl_str_mv |
Permanyer Publications |
| dc.source.none.fl_str_mv |
reponame:CONCYTEC-Institucional instname:Consejo Nacional de Ciencia Tecnología e Innovación instacron:CONCYTEC |
| instname_str |
Consejo Nacional de Ciencia Tecnología e Innovación |
| instacron_str |
CONCYTEC |
| institution |
CONCYTEC |
| reponame_str |
CONCYTEC-Institucional |
| collection |
CONCYTEC-Institucional |
| repository.name.fl_str_mv |
Repositorio Institucional CONCYTEC |
| repository.mail.fl_str_mv |
repositorio@concytec.gob.pe |
| _version_ |
1844883019120246784 |
| spelling |
Publicationrp02620600rp02617600rp02618600rp02619600Tume, LPaco, KUbidia-Incio, RMoya, J2024-05-30T23:13:38Z2024-05-30T23:13:38Z2016https://hdl.handle.net/20.500.12390/959https://doi.org/10.1016/j.gamo.2016.01.003457388700019Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome. © 2016 Sociedad Mexicana de Oncología.Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica - ConcytecengPermanyer PublicationsGaceta Mexicana de Oncologíainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/Breast cancerCD133ImmunotherapyCD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapyinfo:eu-repo/semantics/articlereponame:CONCYTEC-Institucionalinstname:Consejo Nacional de Ciencia Tecnología e Innovacióninstacron:CONCYTEC#PLACEHOLDER_PARENT_METADATA_VALUE#20.500.12390/959oai:repositorio.concytec.gob.pe:20.500.12390/9592025-09-22 14:24:41.153https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_14cbinfo:eu-repo/semantics/closedAccessmetadata only accesshttps://repositorio.concytec.gob.peRepositorio Institucional CONCYTECrepositorio@concytec.gob.pe#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="b64caff4-0236-4d1b-8d41-fa1b2e01ce17"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy</Title> <PublishedIn> <Publication> <Title>Gaceta Mexicana de Oncología</Title> </Publication> </PublishedIn> <PublicationDate>2016</PublicationDate> <DOI>https://doi.org/10.1016/j.gamo.2016.01.003</DOI> <ISI-Number>457388700019</ISI-Number> <Authors> <Author> <DisplayName>Tume, L</DisplayName> <Person id="rp02620" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Paco, K</DisplayName> <Person id="rp02617" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Ubidia-Incio, R</DisplayName> <Person id="rp02618" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Moya, J</DisplayName> <Person id="rp02619" /> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Permanyer Publications</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>https://creativecommons.org/licenses/by/4.0/</License> <Keyword>Breast cancer</Keyword> <Keyword>CD133</Keyword> <Keyword>Immunotherapy</Keyword> <Abstract>Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome. © 2016 Sociedad Mexicana de Oncología.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication> -1 |
| score |
13.909121 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
